Outcomes-based virtual care contracts put vendor fees at risk
Teladoc's move to tie payment to results signals that virtual care buyers will soon need baseline data, attribution rules and downside modeling before they sign another telehealth renewal.
For most of the past decade, buying virtual care meant buying access. A health plan or employer paid a per-member-per-month fee, a vendor stood up a network, and everyone argued about ROI afterward with incompatible spreadsheets. That arrangement is starting to crack. Fierce Healthcare reported on July 23, 2026 that Teladoc Health introduced a virtual care model for employers and health plans that ties payment to results, and once the largest public vendor in the category is willing to write outcomes-based virtual care contracts, the question for every buyer with a renewal in the next two quarters changes from whether to ask for risk sharing to whether they are equipped to administer it.
Why the market leader moved first
Pure access pricing worked when virtual care was scarce. It is a harder sell in a market where Becker's Hospital Review just published a list of 272 telehealth companies worth knowing in 2026. When buyers can name a dozen credible alternatives for any given use case, differentiating on price alone compresses margin. Differentiating on contract structure does something else: it separates vendors who have measured their own performance from vendors who have not.
Capital is not the constraint. Fierce Healthcare's fundraising tracker for 2026 shows money still moving into the sector, including a $25 million round for Arintra and $75 million for Happy Health. Well-funded vendors can afford to put a slice of fees at risk in exchange for a longer contract and a larger book of business. Thinly capitalized ones cannot, which is precisely why performance terms are becoming a de facto screening tool during procurement.
There is also a policy driver. Congress has repeatedly extended Medicare telehealth flexibilities in short increments rather than making them permanent, with trackers from K&L Gates and RCPA following an extension through Jan. 30, 2026 and R Street publishing a policy status check the same month. Buyers operating under that kind of reimbursement uncertainty are understandably reluctant to lock in multi-year fixed fees. Leaders should confirm the current statutory position before it shapes a contract term.
If "we cannot measure that" stops being an acceptable vendor answer, it also stops being an acceptable buyer answer.
Third-party scoring arrives at the same time
Performance pricing is easier to negotiate when someone outside the transaction is publishing quality signals. Fierce Healthcare's weekly rundown noted that U.S. News & World Report has begun ranking GLP-1 telehealth platforms, a category that has drawn heavy consumer spend and heavy clinical skepticism in roughly equal measure. Independent scoring of virtual care will not settle a contract dispute, but it changes the negotiating table. A vendor that ranks poorly on a public list has less leverage to argue that outcomes cannot be measured.
Healthcare leaders should also pull the evaluation literature into procurement rather than leaving it with the innovation team. KLAS Research and the Peterson Health Technology Institute have both been assessing digital health categories on effectiveness and economic impact, and those findings are more useful during a contract negotiation than after a renewal has been signed.
What buyers need before they can accept risk sharing
The uncomfortable implication of outcomes-based contracting is symmetrical. If "we cannot measure that" stops being an acceptable vendor answer, it also stops being an acceptable buyer answer. Most health systems and plans cannot currently produce a clean baseline for virtual care utilization, downstream cost or engagement by population segment. Without one, a performance clause is unenforceable in either direction.
Three technical prerequisites matter most. First, a documented baseline period with an agreed methodology, ideally covering at least four quarters so seasonality does not distort the comparison. Second, attribution rules that specify how a member is assigned to the virtual care intervention, what counts as an avoided emergency department visit or admission, and how concurrent programs are handled. Third, data rights and integration terms strong enough to adjudicate a claim, including access to encounter-level data, defined refresh cadence, and the right to audit the vendor's calculations rather than accept a dashboard.
Interoperability is not a side issue here. If virtual care encounters do not flow into the EHR in a structured, timely way, the organization cannot independently verify what the vendor reports. That is a CIO problem before it is a CFO problem.
How the financial exposure changes
Under a flat fee, the worst case is overpaying for underused access. Under a performance contract, the risk profile is different and boards should see it modeled both ways. If the vendor hits its targets, the organization may owe more than it would have under PMPM pricing, and finance needs that upside payment budgeted rather than treated as a surprise. If the vendor misses, the organization needs to know what it actually recovers, how quickly, and whether recovery is capped.
Legal exposure shifts too. The dispute of the future is not about license terms, it is about attribution. Expect arguments over whether a reduction in utilization was caused by the virtual care program, by a benefit design change, or by a shift in the underlying population. Contracts should name the arbiter, the data set of record and the remedy sequence in advance. Procurement teams that treat these as boilerplate will discover otherwise in year two.
A practical sequence for the next two renewal cycles
Leaders do not need to convert the entire virtual care portfolio at once. A workable approach is to start with one contained use case where the outcome is measurable and the data already exists, such as behavioral health follow-up adherence or chronic condition monitoring for a defined cohort. Put a modest share of fees at risk, run it for a full year, and use the experience to build institutional capability in attribution and audit.
In parallel, ask every incumbent vendor a simple question during renewal talks: what portion of your fee are you willing to place at risk, and against what metric. The answers will sort the market faster than another round of demos. Vendors that decline are not necessarily poor performers, but the refusal is information. So is a proposal that puts fees at risk against metrics the vendor alone controls and reports.
